Mark J. Gergen

2021 - Poseida Therapeutics

In 2021, Mark J. Gergen earned a total compensation of $2.8M as Chief Executive Officer and President and former Chief Business Officer at Poseida Therapeutics, a 96% increase compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$187,450
Option Awards$2,164,381
Salary$462,833
Other$9,252
Total$2,823,916

Gergen received $2.2M in option awards, accounting for 77% of the total pay in 2021.

Gergen also received $187.5K in non-equity incentive plan, $462.8K in salary and $9.3K in other compensation.

Rankings

In 2021, Mark J. Gergen's compensation ranked 4,663rd out of 12,415 executives tracked by ExecPay. In other words, Gergen earned more than 62.4% of executives.

ClassificationRankingPercentile
All
4,663
out of 12,415
62nd
Division
Manufacturing
1,934
out of 5,505
65th
Major group
Chemicals And Allied Products
809
out of 2,375
66th
Industry group
Drugs
722
out of 2,096
66th
Industry
Biological Products, Except Diagnostic Substances
182
out of 449
60th
Source: SEC filing on April 27, 2022.

Gergen's colleagues

We found three more compensation records of executives who worked with Mark J. Gergen at Poseida Therapeutics in 2021.

2021

Eric Ostertag

Poseida Therapeutics

Chief Executive Officer

2021

Matthew Spear

Poseida Therapeutics

Chief Medical Officer

2021

Harry Leonhardt

Poseida Therapeutics

General Counsel

News

In-depth

You may also like